Regeneron reports Pasatru data and Citi holds Regeneron stock

Published on 10/13/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pasatru produced zero new lesions versus 9 for placebo in the 84-week trial. Regeneron stock costs EUR 687.20 on October 13, 2026.

Key points in brief

Regeneron reported 84-week Pasatru results showing zero new lesions versus 9 for placebo in the OPTIMA extension.
The trial enrolled 63 adults, while one high-dose patient had a flare-up versus 17 on placebo.
Regeneron stock was trading at EUR 687.20 at Lang & Schwarz on October 13, 2026.
Third-quarter results are scheduled for October 30, 2026, before U.S. markets open.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron Pharmaceuticals, Inc. (ISIN US75886F1075) reported positive 84-week Pasatru results on October 12, 2026, with zero new heterotopic ossification lesions versus 9 for placebo. Markets Insider also reported on October 12, 2026, that Citi maintained a Hold rating and set a USD 740.00 price target for Regeneron stock.

Pasatru extends its clinical signal

The Phase 3 OPTIMA extension included 63 adults with fibrodysplasia ossificans progressiva, and 58 participants completed the double-blind extension through at least 84 weeks, according to GlobeNewswire. The company said the study had already shown a 90 percent or greater reduction in new lesions at 56 weeks.

The flare-up comparison adds a second quantified signal. At week 84, the high Pasatru dose recorded 1 clinician-assessed flare-up, compared with 17 for placebo and 14 for the lower dose, while skin and soft tissue infections occurred in 78 percent, 53 percent and 33 percent of the respective groups, GlobeNewswire reported. All reported infections were resolved with further management, and no patients discontinued treatment because of infection.

Three dated events shape the story

On October 1, 2026, Regeneron reported Phase 2 COURAGE results in which trevogrumab preserved nearly 70 percent of thigh muscle that would otherwise have been lost with semaglutide alone, according to Finanznachrichten. On October 2, 2026, Investor-SMS reported that Jefferies raised its Regeneron target from USD 870.00 to USD 930.00. On October 12, 2026, the Pasatru extension showed zero new lesions versus 9 for placebo.

What does the next report add?

Regeneron generated USD 4.29 billion of revenue in the second quarter of 2026, up from USD 3.68 billion in the year-earlier quarter, while net profit declined to USD 1.30 billion from USD 1.39 billion, Markets Insider reported. That combination leaves the October 30, 2026, report important for investors assessing whether revenue growth is translating into earnings growth.

Regeneron scheduled its third-quarter 2026 results for October 30, 2026, before U.S. financial markets open, with a conference call at 8:30 a.m. Eastern Time. The date gives the market a defined checkpoint after the Pasatru data and ahead of the next earnings update.

Regeneron stock holds a dated price point

Regeneron stock was trading at EUR 687.20 at Lang & Schwarz on October 13, 2026, at 12:00 p.m. CEST. The primary Nasdaq listing was last quoted at USD 762.81 on October 12, 2026, with a 52-week range of USD 553.87 to USD 859.34 and market capitalization of USD 78.6 billion. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.